nodes	percent_of_prediction	percent_of_DWPC	metapath
Methimazole—CYP2A6—Methoxsalen—psoriasis	0.113	0.142	CbGbCtD
Methimazole—CYP1A2—Clobetasol propionate—psoriasis	0.0822	0.103	CbGbCtD
Methimazole—CYP2A6—Prednisolone—psoriasis	0.055	0.069	CbGbCtD
Methimazole—CYP2B6—Cholecalciferol—psoriasis	0.0488	0.0612	CbGbCtD
Methimazole—CYP1A2—Methoxsalen—psoriasis	0.0432	0.0541	CbGbCtD
Methimazole—CYP2D6—Hydroxyurea—psoriasis	0.0389	0.0488	CbGbCtD
Methimazole—CYP2A6—Dexamethasone—psoriasis	0.0324	0.0407	CbGbCtD
Methimazole—CYP2C19—Cholecalciferol—psoriasis	0.031	0.0389	CbGbCtD
Methimazole—CYP3A4—Calcitriol—psoriasis	0.0291	0.0365	CbGbCtD
Methimazole—CYP2C9—Cholecalciferol—psoriasis	0.0258	0.0323	CbGbCtD
Methimazole—CYP2D6—Cholecalciferol—psoriasis	0.0236	0.0296	CbGbCtD
Methimazole—CYP3A4—Methoxsalen—psoriasis	0.0226	0.0284	CbGbCtD
Methimazole—CYP2C19—Prednisone—psoriasis	0.0215	0.0269	CbGbCtD
Methimazole—CYP2E1—Dexamethasone—psoriasis	0.0214	0.0268	CbGbCtD
Methimazole—CYP2B6—Dexamethasone—psoriasis	0.0211	0.0265	CbGbCtD
Methimazole—CYP2C19—Cyclosporine—psoriasis	0.0204	0.0255	CbGbCtD
Methimazole—CYP2C9—Cyclosporine—psoriasis	0.0169	0.0212	CbGbCtD
Methimazole—CYP2D6—Cyclosporine—psoriasis	0.0155	0.0194	CbGbCtD
Methimazole—CYP3A4—Cholecalciferol—psoriasis	0.015	0.0188	CbGbCtD
Methimazole—CYP2C19—Dexamethasone—psoriasis	0.0134	0.0168	CbGbCtD
Methimazole—CYP3A4—Mycophenolate mofetil—psoriasis	0.013	0.0163	CbGbCtD
Methimazole—CYP3A4—Triamcinolone—psoriasis	0.013	0.0163	CbGbCtD
Methimazole—CYP2C9—Dexamethasone—psoriasis	0.0111	0.014	CbGbCtD
Methimazole—CYP3A4—Betamethasone—psoriasis	0.0111	0.014	CbGbCtD
Methimazole—CYP3A4—Prednisolone—psoriasis	0.011	0.0138	CbGbCtD
Methimazole—CYP3A4—Hydrocortisone—psoriasis	0.0104	0.0131	CbGbCtD
Methimazole—CYP3A4—Prednisone—psoriasis	0.0104	0.013	CbGbCtD
Methimazole—CYP2D6—Dexamethasone—psoriasis	0.0102	0.0128	CbGbCtD
Methimazole—CYP3A4—Cyclosporine—psoriasis	0.00984	0.0123	CbGbCtD
Methimazole—CYP3A4—Dexamethasone—psoriasis	0.00648	0.00813	CbGbCtD
Methimazole—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.0035	0.0632	CbGpPWpGaD
Methimazole—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00283	0.051	CbGpPWpGaD
Methimazole—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00277	0.0499	CbGpPWpGaD
Methimazole—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00217	0.0392	CbGpPWpGaD
Methimazole—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00214	0.0385	CbGpPWpGaD
Methimazole—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00196	0.0354	CbGpPWpGaD
Methimazole—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00195	0.0351	CbGpPWpGaD
Methimazole—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00183	0.0331	CbGpPWpGaD
Methimazole—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00175	0.0316	CbGpPWpGaD
Methimazole—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00172	0.031	CbGpPWpGaD
Methimazole—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00132	0.0239	CbGpPWpGaD
Methimazole—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00122	0.022	CbGpPWpGaD
Methimazole—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00121	0.0218	CbGpPWpGaD
Methimazole—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00103	0.0186	CbGpPWpGaD
Methimazole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000902	0.0163	CbGpPWpGaD
Methimazole—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00089	0.0161	CbGpPWpGaD
Methimazole—Drowsiness—Hydroxyurea—psoriasis	0.000843	0.00573	CcSEcCtD
Methimazole—Neuropathy peripheral—Hydroxyurea—psoriasis	0.000827	0.00561	CcSEcCtD
Methimazole—Myalgia—Calcitriol—psoriasis	0.000803	0.00545	CcSEcCtD
Methimazole—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000796	0.0144	CbGpPWpGaD
Methimazole—Pruritus—Fluocinonide—psoriasis	0.000775	0.00526	CcSEcCtD
Methimazole—Rash—Clobetasol propionate—psoriasis	0.000765	0.0052	CcSEcCtD
Methimazole—Dermatitis—Clobetasol propionate—psoriasis	0.000765	0.00519	CcSEcCtD
Methimazole—Dyspepsia—Methoxsalen—psoriasis	0.000761	0.00516	CcSEcCtD
Methimazole—Headache—Clobetasol propionate—psoriasis	0.00076	0.00516	CcSEcCtD
Methimazole—Vertigo—Fluocinolone Acetonide—psoriasis	0.000752	0.00511	CcSEcCtD
Methimazole—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000731	0.0132	CbGpPWpGaD
Methimazole—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000728	0.0131	CbGpPWpGaD
Methimazole—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000718	0.013	CbGpPWpGaD
Methimazole—Myalgia—Acitretin—psoriasis	0.000715	0.00485	CcSEcCtD
Methimazole—Arthralgia—Acitretin—psoriasis	0.000715	0.00485	CcSEcCtD
Methimazole—Arthralgia—Fluocinolone Acetonide—psoriasis	0.000713	0.00484	CcSEcCtD
Methimazole—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000713	0.0129	CbGpPWpGaD
Methimazole—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000703	0.0127	CbGpPWpGaD
Methimazole—Musculoskeletal discomfort—Calcitriol—psoriasis	0.000702	0.00476	CcSEcCtD
Methimazole—Rash—Beclomethasone—psoriasis	0.000697	0.00473	CcSEcCtD
Methimazole—Dermatitis—Beclomethasone—psoriasis	0.000696	0.00472	CcSEcCtD
Methimazole—Neuropathy peripheral—Mycophenolic acid—psoriasis	0.000692	0.0047	CcSEcCtD
Methimazole—Headache—Beclomethasone—psoriasis	0.000692	0.0047	CcSEcCtD
Methimazole—Rash—Fluocinonide—psoriasis	0.00069	0.00469	CcSEcCtD
Methimazole—Dermatitis—Fluocinonide—psoriasis	0.00069	0.00468	CcSEcCtD
Methimazole—Jaundice—Mycophenolic acid—psoriasis	0.000689	0.00467	CcSEcCtD
Methimazole—Urticaria—Methoxsalen—psoriasis	0.000686	0.00466	CcSEcCtD
Methimazole—Headache—Fluocinonide—psoriasis	0.000686	0.00466	CcSEcCtD
Methimazole—Oedema—Acitretin—psoriasis	0.000685	0.00465	CcSEcCtD
Methimazole—Somnolence—Calcitriol—psoriasis	0.000685	0.00465	CcSEcCtD
Methimazole—Oedema—Fluocinolone Acetonide—psoriasis	0.000683	0.00464	CcSEcCtD
Methimazole—Body temperature increased—Methoxsalen—psoriasis	0.000683	0.00464	CcSEcCtD
Methimazole—Alopecia—Hydroxyurea—psoriasis	0.000669	0.00454	CcSEcCtD
Methimazole—Agranulocytosis—Mycophenolic acid—psoriasis	0.000659	0.00448	CcSEcCtD
Methimazole—Nausea—Beclomethasone—psoriasis	0.000656	0.00446	CcSEcCtD
Methimazole—Hepatitis—Mycophenolic acid—psoriasis	0.000634	0.0043	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Acitretin—psoriasis	0.000624	0.00424	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Fluocinolone Acetonide—psoriasis	0.000622	0.00423	CcSEcCtD
Methimazole—Paraesthesia—Acitretin—psoriasis	0.000615	0.00418	CcSEcCtD
Methimazole—Urticaria—Calcitriol—psoriasis	0.000612	0.00415	CcSEcCtD
Methimazole—Pruritus—Methoxsalen—psoriasis	0.000611	0.00415	CcSEcCtD
Methimazole—Somnolence—Acitretin—psoriasis	0.000609	0.00414	CcSEcCtD
Methimazole—Body temperature increased—Calcitriol—psoriasis	0.000609	0.00413	CcSEcCtD
Methimazole—Dyspepsia—Acitretin—psoriasis	0.000603	0.00409	CcSEcCtD
Methimazole—Leukopenia—Hydroxyurea—psoriasis	0.00059	0.00401	CcSEcCtD
Methimazole—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00059	0.0106	CbGpPWpGaD
Methimazole—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000578	0.0104	CbGpPWpGaD
Methimazole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000565	0.0102	CbGpPWpGaD
Methimazole—Alopecia—Mycophenolic acid—psoriasis	0.00056	0.0038	CcSEcCtD
Methimazole—Neuropathy peripheral—Cyclosporine—psoriasis	0.00056	0.0038	CcSEcCtD
Methimazole—TPO—Differentiation Pathway—VEGFA—psoriasis	0.00056	0.0101	CbGpPWpGaD
Methimazole—Jaundice—Cyclosporine—psoriasis	0.000557	0.00378	CcSEcCtD
Methimazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00055	0.00992	CbGpPWpGaD
Methimazole—Neuropathy peripheral—Mycophenolate mofetil—psoriasis	0.000546	0.00371	CcSEcCtD
Methimazole—Pruritus—Calcitriol—psoriasis	0.000545	0.0037	CcSEcCtD
Methimazole—Rash—Methoxsalen—psoriasis	0.000545	0.0037	CcSEcCtD
Methimazole—Dermatitis—Methoxsalen—psoriasis	0.000544	0.0037	CcSEcCtD
Methimazole—Urticaria—Acitretin—psoriasis	0.000544	0.0037	CcSEcCtD
Methimazole—Jaundice—Mycophenolate mofetil—psoriasis	0.000543	0.00369	CcSEcCtD
Methimazole—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000543	0.00979	CbGpPWpGaD
Methimazole—Body temperature increased—Acitretin—psoriasis	0.000542	0.00368	CcSEcCtD
Methimazole—Headache—Methoxsalen—psoriasis	0.000541	0.00367	CcSEcCtD
Methimazole—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.00054	0.00367	CcSEcCtD
Methimazole—Oedema—Hydroxyurea—psoriasis	0.000538	0.00365	CcSEcCtD
Methimazole—Aplastic anaemia—Methotrexate—psoriasis	0.00053	0.0036	CcSEcCtD
Methimazole—Thrombocytopenia—Hydroxyurea—psoriasis	0.000527	0.00358	CcSEcCtD
Methimazole—Agranulocytosis—Mycophenolate mofetil—psoriasis	0.00052	0.00353	CcSEcCtD
Methimazole—Nausea—Methoxsalen—psoriasis	0.000513	0.00348	CcSEcCtD
Methimazole—Hepatitis—Cyclosporine—psoriasis	0.000513	0.00348	CcSEcCtD
Methimazole—Neuropathy peripheral—Prednisolone—psoriasis	0.00051	0.00346	CcSEcCtD
Methimazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000506	0.00912	CbGpPWpGaD
Methimazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000501	0.00904	CbGpPWpGaD
Methimazole—Hepatitis—Mycophenolate mofetil—psoriasis	0.0005	0.0034	CcSEcCtD
Methimazole—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000499	0.009	CbGpPWpGaD
Methimazole—Neuropathy peripheral—Hydrocortisone—psoriasis	0.000498	0.00338	CcSEcCtD
Methimazole—Vertigo—Mycophenolic acid—psoriasis	0.000496	0.00337	CcSEcCtD
Methimazole—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000495	0.00892	CbGpPWpGaD
Methimazole—Leukopenia—Mycophenolic acid—psoriasis	0.000494	0.00335	CcSEcCtD
Methimazole—Vomiting—Calcitriol—psoriasis	0.00049	0.00332	CcSEcCtD
Methimazole—Rash—Calcitriol—psoriasis	0.000486	0.0033	CcSEcCtD
Methimazole—Dermatitis—Calcitriol—psoriasis	0.000485	0.00329	CcSEcCtD
Methimazole—Pruritus—Acitretin—psoriasis	0.000485	0.00329	CcSEcCtD
Methimazole—Pruritus—Fluocinolone Acetonide—psoriasis	0.000483	0.00328	CcSEcCtD
Methimazole—Headache—Calcitriol—psoriasis	0.000482	0.00328	CcSEcCtD
Methimazole—Lymphadenopathy—Methotrexate—psoriasis	0.00048	0.00326	CcSEcCtD
Methimazole—Somnolence—Hydroxyurea—psoriasis	0.000478	0.00325	CcSEcCtD
Methimazole—Dyspepsia—Hydroxyurea—psoriasis	0.000473	0.00321	CcSEcCtD
Methimazole—Arthralgia—Mycophenolic acid—psoriasis	0.00047	0.00319	CcSEcCtD
Methimazole—Myalgia—Mycophenolic acid—psoriasis	0.00047	0.00319	CcSEcCtD
Methimazole—Neuropathy peripheral—Triamcinolone—psoriasis	0.000469	0.00318	CcSEcCtD
Methimazole—Nausea—Calcitriol—psoriasis	0.000457	0.00311	CcSEcCtD
Methimazole—Alopecia—Cyclosporine—psoriasis	0.000453	0.00308	CcSEcCtD
Methimazole—Oedema—Mycophenolic acid—psoriasis	0.000451	0.00306	CcSEcCtD
Methimazole—TPO—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	0.000448	0.00808	CbGpPWpGaD
Methimazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000446	0.00804	CbGpPWpGaD
Methimazole—Alopecia—Mycophenolate mofetil—psoriasis	0.000442	0.003	CcSEcCtD
Methimazole—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000441	0.00299	CcSEcCtD
Methimazole—Vomiting—Acitretin—psoriasis	0.000436	0.00296	CcSEcCtD
Methimazole—Vomiting—Fluocinolone Acetonide—psoriasis	0.000434	0.00295	CcSEcCtD
Methimazole—Rash—Acitretin—psoriasis	0.000432	0.00293	CcSEcCtD
Methimazole—Dermatitis—Acitretin—psoriasis	0.000432	0.00293	CcSEcCtD
Methimazole—Rash—Fluocinolone Acetonide—psoriasis	0.000431	0.00292	CcSEcCtD
Methimazole—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00043	0.00292	CcSEcCtD
Methimazole—Headache—Acitretin—psoriasis	0.000429	0.00291	CcSEcCtD
Methimazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000428	0.00773	CbGpPWpGaD
Methimazole—Headache—Fluocinolone Acetonide—psoriasis	0.000428	0.00291	CcSEcCtD
Methimazole—Neuropathy peripheral—Betamethasone—psoriasis	0.000425	0.00289	CcSEcCtD
Methimazole—Neuropathy peripheral—Dexamethasone—psoriasis	0.000425	0.00289	CcSEcCtD
Methimazole—Body temperature increased—Hydroxyurea—psoriasis	0.000425	0.00289	CcSEcCtD
Methimazole—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000423	0.00762	CbGpPWpGaD
Methimazole—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.00041	0.00279	CcSEcCtD
Methimazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00041	0.00739	CbGpPWpGaD
Methimazole—Nausea—Acitretin—psoriasis	0.000407	0.00276	CcSEcCtD
Methimazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000406	0.00733	CbGpPWpGaD
Methimazole—Nausea—Fluocinolone Acetonide—psoriasis	0.000406	0.00276	CcSEcCtD
Methimazole—Paraesthesia—Mycophenolic acid—psoriasis	0.000405	0.00275	CcSEcCtD
Methimazole—Vertigo—Cyclosporine—psoriasis	0.000401	0.00272	CcSEcCtD
Methimazole—Somnolence—Mycophenolic acid—psoriasis	0.000401	0.00272	CcSEcCtD
Methimazole—Leukopenia—Cyclosporine—psoriasis	0.0004	0.00271	CcSEcCtD
Methimazole—Dyspepsia—Mycophenolic acid—psoriasis	0.000397	0.00269	CcSEcCtD
Methimazole—Vertigo—Mycophenolate mofetil—psoriasis	0.000391	0.00266	CcSEcCtD
Methimazole—Leukopenia—Mycophenolate mofetil—psoriasis	0.00039	0.00265	CcSEcCtD
Methimazole—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000388	0.007	CbGpPWpGaD
Methimazole—TPO—Differentiation Pathway—IL6—psoriasis	0.000387	0.00698	CbGpPWpGaD
Methimazole—Myalgia—Cyclosporine—psoriasis	0.00038	0.00258	CcSEcCtD
Methimazole—Arthralgia—Cyclosporine—psoriasis	0.00038	0.00258	CcSEcCtD
Methimazole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000374	0.00675	CbGpPWpGaD
Methimazole—Myalgia—Mycophenolate mofetil—psoriasis	0.000371	0.00252	CcSEcCtD
Methimazole—Arthralgia—Mycophenolate mofetil—psoriasis	0.000371	0.00252	CcSEcCtD
Methimazole—Neuropathy peripheral—Prednisone—psoriasis	0.00037	0.00251	CcSEcCtD
Methimazole—Vertigo—Prednisolone—psoriasis	0.000365	0.00248	CcSEcCtD
Methimazole—Oedema—Cyclosporine—psoriasis	0.000364	0.00247	CcSEcCtD
Methimazole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.00036	0.0065	CbGpPWpGaD
Methimazole—Thrombocytopenia—Cyclosporine—psoriasis	0.000357	0.00242	CcSEcCtD
Methimazole—Vertigo—Hydrocortisone—psoriasis	0.000357	0.00242	CcSEcCtD
Methimazole—Body temperature increased—Mycophenolic acid—psoriasis	0.000356	0.00242	CcSEcCtD
Methimazole—Oedema—Mycophenolate mofetil—psoriasis	0.000356	0.00241	CcSEcCtD
Methimazole—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000348	0.00236	CcSEcCtD
Methimazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000347	0.00626	CbGpPWpGaD
Methimazole—Alopecia—Betamethasone—psoriasis	0.000344	0.00234	CcSEcCtD
Methimazole—Alopecia—Dexamethasone—psoriasis	0.000344	0.00234	CcSEcCtD
Methimazole—Vomiting—Hydroxyurea—psoriasis	0.000342	0.00232	CcSEcCtD
Methimazole—Rash—Hydroxyurea—psoriasis	0.000339	0.0023	CcSEcCtD
Methimazole—Dermatitis—Hydroxyurea—psoriasis	0.000339	0.0023	CcSEcCtD
Methimazole—Myalgia—Hydrocortisone—psoriasis	0.000338	0.00229	CcSEcCtD
Methimazole—Headache—Hydroxyurea—psoriasis	0.000337	0.00229	CcSEcCtD
Methimazole—Vertigo—Triamcinolone—psoriasis	0.000336	0.00228	CcSEcCtD
Methimazole—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000334	0.00603	CbGpPWpGaD
Methimazole—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000332	0.00225	CcSEcCtD
Methimazole—Oedema—Prednisolone—psoriasis	0.000332	0.00225	CcSEcCtD
Methimazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000331	0.00596	CbGpPWpGaD
Methimazole—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000327	0.0059	CbGpPWpGaD
Methimazole—Paraesthesia—Cyclosporine—psoriasis	0.000327	0.00222	CcSEcCtD
Methimazole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000327	0.0059	CbGpPWpGaD
Methimazole—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000326	0.00588	CbGpPWpGaD
Methimazole—Somnolence—Cyclosporine—psoriasis	0.000324	0.0022	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000324	0.0022	CcSEcCtD
Methimazole—Oedema—Hydrocortisone—psoriasis	0.000324	0.0022	CcSEcCtD
Methimazole—TPO—Metabolism—NDUFA5—psoriasis	0.000322	0.00581	CbGpPWpGaD
Methimazole—Dyspepsia—Cyclosporine—psoriasis	0.000321	0.00218	CcSEcCtD
Methimazole—Nausea—Hydroxyurea—psoriasis	0.00032	0.00217	CcSEcCtD
Methimazole—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000319	0.00217	CcSEcCtD
Methimazole—Pruritus—Mycophenolic acid—psoriasis	0.000319	0.00216	CcSEcCtD
Methimazole—Myalgia—Triamcinolone—psoriasis	0.000318	0.00216	CcSEcCtD
Methimazole—Somnolence—Mycophenolate mofetil—psoriasis	0.000316	0.00215	CcSEcCtD
Methimazole—Drowsiness—Methotrexate—psoriasis	0.000316	0.00214	CcSEcCtD
Methimazole—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000313	0.00565	CbGpPWpGaD
Methimazole—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000313	0.00212	CcSEcCtD
Methimazole—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000309	0.00557	CbGpPWpGaD
Methimazole—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000307	0.00553	CbGpPWpGaD
Methimazole—Oedema—Triamcinolone—psoriasis	0.000305	0.00207	CcSEcCtD
Methimazole—Vertigo—Betamethasone—psoriasis	0.000305	0.00207	CcSEcCtD
Methimazole—Vertigo—Dexamethasone—psoriasis	0.000305	0.00207	CcSEcCtD
Methimazole—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000303	0.00546	CbGpPWpGaD
Methimazole—Alopecia—Prednisone—psoriasis	0.0003	0.00204	CcSEcCtD
Methimazole—Paraesthesia—Prednisolone—psoriasis	0.000298	0.00202	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000295	0.002	CcSEcCtD
Methimazole—Agranulocytosis—Methotrexate—psoriasis	0.000295	0.002	CcSEcCtD
Methimazole—Paraesthesia—Hydrocortisone—psoriasis	0.000291	0.00197	CcSEcCtD
Methimazole—Urticaria—Cyclosporine—psoriasis	0.00029	0.00197	CcSEcCtD
Methimazole—Myalgia—Betamethasone—psoriasis	0.000289	0.00196	CcSEcCtD
Methimazole—Myalgia—Dexamethasone—psoriasis	0.000289	0.00196	CcSEcCtD
Methimazole—Body temperature increased—Cyclosporine—psoriasis	0.000288	0.00196	CcSEcCtD
Methimazole—Vomiting—Mycophenolic acid—psoriasis	0.000286	0.00194	CcSEcCtD
Methimazole—Dyspepsia—Hydrocortisone—psoriasis	0.000285	0.00194	CcSEcCtD
Methimazole—Rash—Mycophenolic acid—psoriasis	0.000284	0.00193	CcSEcCtD
Methimazole—Dermatitis—Mycophenolic acid—psoriasis	0.000284	0.00193	CcSEcCtD
Methimazole—Hepatitis—Methotrexate—psoriasis	0.000283	0.00192	CcSEcCtD
Methimazole—Urticaria—Mycophenolate mofetil—psoriasis	0.000282	0.00192	CcSEcCtD
Methimazole—Headache—Mycophenolic acid—psoriasis	0.000282	0.00192	CcSEcCtD
Methimazole—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000281	0.00191	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000278	0.00189	CcSEcCtD
Methimazole—Oedema—Dexamethasone—psoriasis	0.000277	0.00188	CcSEcCtD
Methimazole—Oedema—Betamethasone—psoriasis	0.000277	0.00188	CcSEcCtD
Methimazole—Paraesthesia—Triamcinolone—psoriasis	0.000274	0.00186	CcSEcCtD
Methimazole—TPO—Metabolism—CYP2S1—psoriasis	0.000274	0.00494	CbGpPWpGaD
Methimazole—Thrombocytopenia—Betamethasone—psoriasis	0.000271	0.00184	CcSEcCtD
Methimazole—Thrombocytopenia—Dexamethasone—psoriasis	0.000271	0.00184	CcSEcCtD
Methimazole—Dyspepsia—Triamcinolone—psoriasis	0.000268	0.00182	CcSEcCtD
Methimazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000268	0.00483	CbGpPWpGaD
Methimazole—Nausea—Mycophenolic acid—psoriasis	0.000268	0.00182	CcSEcCtD
Methimazole—Vertigo—Prednisone—psoriasis	0.000265	0.0018	CcSEcCtD
Methimazole—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000265	0.00478	CbGpPWpGaD
Methimazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000264	0.00477	CbGpPWpGaD
Methimazole—Urticaria—Prednisolone—psoriasis	0.000263	0.00179	CcSEcCtD
Methimazole—Pruritus—Cyclosporine—psoriasis	0.000258	0.00175	CcSEcCtD
Methimazole—Urticaria—Hydrocortisone—psoriasis	0.000257	0.00175	CcSEcCtD
Methimazole—Body temperature increased—Hydrocortisone—psoriasis	0.000256	0.00174	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000252	0.00171	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000252	0.00171	CcSEcCtD
Methimazole—Pruritus—Mycophenolate mofetil—psoriasis	0.000252	0.00171	CcSEcCtD
Methimazole—Arthralgia—Prednisone—psoriasis	0.000251	0.00171	CcSEcCtD
Methimazole—Myalgia—Prednisone—psoriasis	0.000251	0.00171	CcSEcCtD
Methimazole—Alopecia—Methotrexate—psoriasis	0.000251	0.0017	CcSEcCtD
Methimazole—Paraesthesia—Betamethasone—psoriasis	0.000248	0.00169	CcSEcCtD
Methimazole—Paraesthesia—Dexamethasone—psoriasis	0.000248	0.00169	CcSEcCtD
Methimazole—Dyspepsia—Dexamethasone—psoriasis	0.000244	0.00165	CcSEcCtD
Methimazole—Dyspepsia—Betamethasone—psoriasis	0.000244	0.00165	CcSEcCtD
Methimazole—Urticaria—Triamcinolone—psoriasis	0.000242	0.00164	CcSEcCtD
Methimazole—Body temperature increased—Triamcinolone—psoriasis	0.000241	0.00164	CcSEcCtD
Methimazole—Oedema—Prednisone—psoriasis	0.000241	0.00164	CcSEcCtD
Methimazole—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000237	0.00427	CbGpPWpGaD
Methimazole—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000234	0.00421	CbGpPWpGaD
Methimazole—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000233	0.0042	CbGpPWpGaD
Methimazole—Vomiting—Cyclosporine—psoriasis	0.000232	0.00157	CcSEcCtD
Methimazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00023	0.00415	CbGpPWpGaD
Methimazole—Rash—Cyclosporine—psoriasis	0.00023	0.00156	CcSEcCtD
Methimazole—Dermatitis—Cyclosporine—psoriasis	0.00023	0.00156	CcSEcCtD
Methimazole—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.00023	0.00414	CbGpPWpGaD
Methimazole—Pruritus—Hydrocortisone—psoriasis	0.000229	0.00156	CcSEcCtD
Methimazole—Headache—Cyclosporine—psoriasis	0.000228	0.00155	CcSEcCtD
Methimazole—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000228	0.00412	CbGpPWpGaD
Methimazole—Vomiting—Mycophenolate mofetil—psoriasis	0.000226	0.00153	CcSEcCtD
Methimazole—Rash—Mycophenolate mofetil—psoriasis	0.000224	0.00152	CcSEcCtD
Methimazole—Dermatitis—Mycophenolate mofetil—psoriasis	0.000224	0.00152	CcSEcCtD
Methimazole—Headache—Mycophenolate mofetil—psoriasis	0.000223	0.00151	CcSEcCtD
Methimazole—Vertigo—Methotrexate—psoriasis	0.000222	0.00151	CcSEcCtD
Methimazole—Leukopenia—Methotrexate—psoriasis	0.000221	0.0015	CcSEcCtD
Methimazole—Urticaria—Betamethasone—psoriasis	0.00022	0.00149	CcSEcCtD
Methimazole—Urticaria—Dexamethasone—psoriasis	0.00022	0.00149	CcSEcCtD
Methimazole—Musculoskeletal discomfort—Prednisone—psoriasis	0.00022	0.00149	CcSEcCtD
Methimazole—Body temperature increased—Dexamethasone—psoriasis	0.000219	0.00149	CcSEcCtD
Methimazole—Body temperature increased—Betamethasone—psoriasis	0.000219	0.00149	CcSEcCtD
Methimazole—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000218	0.00393	CbGpPWpGaD
Methimazole—Nausea—Cyclosporine—psoriasis	0.000216	0.00147	CcSEcCtD
Methimazole—Paraesthesia—Prednisone—psoriasis	0.000216	0.00147	CcSEcCtD
Methimazole—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000216	0.0039	CbGpPWpGaD
Methimazole—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000216	0.00389	CbGpPWpGaD
Methimazole—Pruritus—Triamcinolone—psoriasis	0.000216	0.00146	CcSEcCtD
Methimazole—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000215	0.00387	CbGpPWpGaD
Methimazole—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000213	0.00384	CbGpPWpGaD
Methimazole—Dyspepsia—Prednisone—psoriasis	0.000212	0.00144	CcSEcCtD
Methimazole—Nausea—Mycophenolate mofetil—psoriasis	0.000211	0.00143	CcSEcCtD
Methimazole—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000211	0.00381	CbGpPWpGaD
Methimazole—Arthralgia—Methotrexate—psoriasis	0.00021	0.00143	CcSEcCtD
Methimazole—Myalgia—Methotrexate—psoriasis	0.00021	0.00143	CcSEcCtD
Methimazole—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.00021	0.00379	CbGpPWpGaD
Methimazole—Rash—Prednisolone—psoriasis	0.000209	0.00142	CcSEcCtD
Methimazole—Dermatitis—Prednisolone—psoriasis	0.000209	0.00142	CcSEcCtD
Methimazole—Headache—Prednisolone—psoriasis	0.000208	0.00141	CcSEcCtD
Methimazole—Vomiting—Hydrocortisone—psoriasis	0.000206	0.0014	CcSEcCtD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000206	0.00371	CbGpPWpGaD
Methimazole—Rash—Hydrocortisone—psoriasis	0.000204	0.00139	CcSEcCtD
Methimazole—Dermatitis—Hydrocortisone—psoriasis	0.000204	0.00139	CcSEcCtD
Methimazole—Headache—Hydrocortisone—psoriasis	0.000203	0.00138	CcSEcCtD
Methimazole—Thrombocytopenia—Methotrexate—psoriasis	0.000197	0.00134	CcSEcCtD
Methimazole—Nausea—Prednisolone—psoriasis	0.000197	0.00134	CcSEcCtD
Methimazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000197	0.00355	CbGpPWpGaD
Methimazole—Pruritus—Dexamethasone—psoriasis	0.000196	0.00133	CcSEcCtD
Methimazole—Pruritus—Betamethasone—psoriasis	0.000196	0.00133	CcSEcCtD
Methimazole—Vomiting—Triamcinolone—psoriasis	0.000194	0.00132	CcSEcCtD
Methimazole—Nausea—Hydrocortisone—psoriasis	0.000192	0.00131	CcSEcCtD
Methimazole—Rash—Triamcinolone—psoriasis	0.000192	0.00131	CcSEcCtD
Methimazole—Dermatitis—Triamcinolone—psoriasis	0.000192	0.0013	CcSEcCtD
Methimazole—Urticaria—Prednisone—psoriasis	0.000191	0.0013	CcSEcCtD
Methimazole—Headache—Triamcinolone—psoriasis	0.000191	0.0013	CcSEcCtD
Methimazole—Body temperature increased—Prednisone—psoriasis	0.000191	0.00129	CcSEcCtD
Methimazole—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000184	0.00333	CbGpPWpGaD
Methimazole—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000184	0.00125	CcSEcCtD
Methimazole—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000182	0.00328	CbGpPWpGaD
Methimazole—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000182	0.00328	CbGpPWpGaD
Methimazole—Nausea—Triamcinolone—psoriasis	0.000181	0.00123	CcSEcCtD
Methimazole—Paraesthesia—Methotrexate—psoriasis	0.000181	0.00123	CcSEcCtD
Methimazole—Somnolence—Methotrexate—psoriasis	0.000179	0.00122	CcSEcCtD
Methimazole—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000179	0.00323	CbGpPWpGaD
Methimazole—Dyspepsia—Methotrexate—psoriasis	0.000177	0.0012	CcSEcCtD
Methimazole—Vomiting—Dexamethasone—psoriasis	0.000176	0.00119	CcSEcCtD
Methimazole—Vomiting—Betamethasone—psoriasis	0.000176	0.00119	CcSEcCtD
Methimazole—Rash—Betamethasone—psoriasis	0.000174	0.00118	CcSEcCtD
Methimazole—Rash—Dexamethasone—psoriasis	0.000174	0.00118	CcSEcCtD
Methimazole—Dermatitis—Betamethasone—psoriasis	0.000174	0.00118	CcSEcCtD
Methimazole—Dermatitis—Dexamethasone—psoriasis	0.000174	0.00118	CcSEcCtD
Methimazole—Headache—Betamethasone—psoriasis	0.000173	0.00118	CcSEcCtD
Methimazole—Headache—Dexamethasone—psoriasis	0.000173	0.00118	CcSEcCtD
Methimazole—Pruritus—Prednisone—psoriasis	0.000171	0.00116	CcSEcCtD
Methimazole—Nausea—Betamethasone—psoriasis	0.000164	0.00112	CcSEcCtD
Methimazole—Nausea—Dexamethasone—psoriasis	0.000164	0.00112	CcSEcCtD
Methimazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000161	0.0029	CbGpPWpGaD
Methimazole—Urticaria—Methotrexate—psoriasis	0.00016	0.00109	CcSEcCtD
Methimazole—Body temperature increased—Methotrexate—psoriasis	0.000159	0.00108	CcSEcCtD
Methimazole—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000159	0.00287	CbGpPWpGaD
Methimazole—Vomiting—Prednisone—psoriasis	0.000153	0.00104	CcSEcCtD
Methimazole—Rash—Prednisone—psoriasis	0.000152	0.00103	CcSEcCtD
Methimazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000152	0.00274	CbGpPWpGaD
Methimazole—Dermatitis—Prednisone—psoriasis	0.000152	0.00103	CcSEcCtD
Methimazole—Headache—Prednisone—psoriasis	0.000151	0.00102	CcSEcCtD
Methimazole—Nausea—Prednisone—psoriasis	0.000143	0.000972	CcSEcCtD
Methimazole—Pruritus—Methotrexate—psoriasis	0.000142	0.000967	CcSEcCtD
Methimazole—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000142	0.00257	CbGpPWpGaD
Methimazole—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.00014	0.00253	CbGpPWpGaD
Methimazole—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000138	0.0025	CbGpPWpGaD
Methimazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000137	0.00247	CbGpPWpGaD
Methimazole—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000137	0.00246	CbGpPWpGaD
Methimazole—TPO—Metabolism—CARM1—psoriasis	0.000134	0.00241	CbGpPWpGaD
Methimazole—Vomiting—Methotrexate—psoriasis	0.000128	0.000869	CcSEcCtD
Methimazole—Rash—Methotrexate—psoriasis	0.000127	0.000862	CcSEcCtD
Methimazole—Dermatitis—Methotrexate—psoriasis	0.000127	0.000861	CcSEcCtD
Methimazole—Headache—Methotrexate—psoriasis	0.000126	0.000857	CcSEcCtD
Methimazole—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000126	0.00226	CbGpPWpGaD
Methimazole—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000123	0.00222	CbGpPWpGaD
Methimazole—Nausea—Methotrexate—psoriasis	0.00012	0.000812	CcSEcCtD
Methimazole—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000106	0.00192	CbGpPWpGaD
Methimazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000106	0.00191	CbGpPWpGaD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.84e-05	0.00159	CbGpPWpGaD
Methimazole—TPO—Metabolism—CAT—psoriasis	8.22e-05	0.00148	CbGpPWpGaD
Methimazole—CYP2A6—Metabolism—NDUFA5—psoriasis	7.81e-05	0.00141	CbGpPWpGaD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.64e-05	0.00138	CbGpPWpGaD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.35e-05	0.00133	CbGpPWpGaD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.67e-05	0.0012	CbGpPWpGaD
Methimazole—CYP2A6—Metabolism—CYP2S1—psoriasis	6.64e-05	0.0012	CbGpPWpGaD
Methimazole—TPO—Metabolism—APOE—psoriasis	6.39e-05	0.00115	CbGpPWpGaD
Methimazole—CYP2B6—Metabolism—NDUFA5—psoriasis	6.3e-05	0.00114	CbGpPWpGaD
Methimazole—CYP2E1—Metabolism—NDUFA5—psoriasis	6.17e-05	0.00111	CbGpPWpGaD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.72e-05	0.00103	CbGpPWpGaD
Methimazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.72e-05	0.00103	CbGpPWpGaD
Methimazole—TPO—Metabolism—PPARG—psoriasis	5.56e-05	0.001	CbGpPWpGaD
Methimazole—CYP2B6—Metabolism—CYP2S1—psoriasis	5.36e-05	0.000966	CbGpPWpGaD
Methimazole—CYP2E1—Metabolism—CYP2S1—psoriasis	5.25e-05	0.000947	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism—NDUFA5—psoriasis	4.76e-05	0.000859	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.44e-05	0.000801	CbGpPWpGaD
Methimazole—CYP2D6—Metabolism—NDUFA5—psoriasis	4.38e-05	0.00079	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism—NDUFA5—psoriasis	4.34e-05	0.000783	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism—CYP2S1—psoriasis	4.05e-05	0.00073	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.05e-05	0.00073	CbGpPWpGaD
Methimazole—CYP2D6—Metabolism—CYP2S1—psoriasis	3.72e-05	0.000672	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism—NDUFA5—psoriasis	3.71e-05	0.000669	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism—CYP2S1—psoriasis	3.69e-05	0.000666	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.46e-05	0.000624	CbGpPWpGaD
Methimazole—CYP2A6—Metabolism—CARM1—psoriasis	3.24e-05	0.000585	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism—CYP2S1—psoriasis	3.15e-05	0.000569	CbGpPWpGaD
Methimazole—CYP3A4—Metabolism—NDUFA5—psoriasis	2.86e-05	0.000516	CbGpPWpGaD
Methimazole—CYP2B6—Metabolism—CARM1—psoriasis	2.62e-05	0.000472	CbGpPWpGaD
Methimazole—CYP2E1—Metabolism—CARM1—psoriasis	2.56e-05	0.000462	CbGpPWpGaD
Methimazole—CYP3A4—Metabolism—CYP2S1—psoriasis	2.43e-05	0.000439	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.12e-05	0.000383	CbGpPWpGaD
Methimazole—CYP2A6—Metabolism—CAT—psoriasis	1.99e-05	0.00036	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism—CARM1—psoriasis	1.98e-05	0.000357	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.93e-05	0.000349	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.85e-05	0.000333	CbGpPWpGaD
Methimazole—CYP2D6—Metabolism—CARM1—psoriasis	1.82e-05	0.000328	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism—CARM1—psoriasis	1.8e-05	0.000325	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.69e-05	0.000304	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.65e-05	0.000298	CbGpPWpGaD
Methimazole—CYP2B6—Metabolism—CAT—psoriasis	1.61e-05	0.00029	CbGpPWpGaD
Methimazole—CYP2E1—Metabolism—CAT—psoriasis	1.58e-05	0.000284	CbGpPWpGaD
Methimazole—CYP2A6—Metabolism—APOE—psoriasis	1.55e-05	0.00028	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism—CARM1—psoriasis	1.54e-05	0.000278	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.44e-05	0.00026	CbGpPWpGaD
Methimazole—CYP2A6—Metabolism—PPARG—psoriasis	1.35e-05	0.000243	CbGpPWpGaD
Methimazole—CYP2B6—Metabolism—APOE—psoriasis	1.25e-05	0.000226	CbGpPWpGaD
Methimazole—CYP2E1—Metabolism—APOE—psoriasis	1.22e-05	0.000221	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism—CAT—psoriasis	1.22e-05	0.000219	CbGpPWpGaD
Methimazole—CYP3A4—Metabolism—CARM1—psoriasis	1.19e-05	0.000214	CbGpPWpGaD
Methimazole—CYP2D6—Metabolism—CAT—psoriasis	1.12e-05	0.000202	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism—CAT—psoriasis	1.11e-05	0.0002	CbGpPWpGaD
Methimazole—CYP2B6—Metabolism—PPARG—psoriasis	1.09e-05	0.000196	CbGpPWpGaD
Methimazole—CYP2E1—Metabolism—PPARG—psoriasis	1.07e-05	0.000192	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism—CAT—psoriasis	9.48e-06	0.000171	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism—APOE—psoriasis	9.45e-06	0.00017	CbGpPWpGaD
Methimazole—CYP2D6—Metabolism—APOE—psoriasis	8.69e-06	0.000157	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism—APOE—psoriasis	8.62e-06	0.000155	CbGpPWpGaD
Methimazole—CYP2C19—Metabolism—PPARG—psoriasis	8.23e-06	0.000148	CbGpPWpGaD
Methimazole—CYP2D6—Metabolism—PPARG—psoriasis	7.57e-06	0.000137	CbGpPWpGaD
Methimazole—CYP2C9—Metabolism—PPARG—psoriasis	7.51e-06	0.000135	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism—APOE—psoriasis	7.36e-06	0.000133	CbGpPWpGaD
Methimazole—CYP3A4—Metabolism—CAT—psoriasis	7.31e-06	0.000132	CbGpPWpGaD
Methimazole—CYP1A2—Metabolism—PPARG—psoriasis	6.41e-06	0.000116	CbGpPWpGaD
Methimazole—CYP3A4—Metabolism—APOE—psoriasis	5.68e-06	0.000102	CbGpPWpGaD
Methimazole—CYP3A4—Metabolism—PPARG—psoriasis	4.95e-06	8.93e-05	CbGpPWpGaD
